Document is current

Article History

Received: 17 October 2024

Revised: 12 January 2025

Accepted: 15 January 2025

First Online: 1 February 2025

Declarations

:

: MF is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology, received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA, participation in Advisory Boards for Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda, scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol Myers Squibb, Lilly, Novartis, Sanofi-Genzyme, he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla; MPA has served on Scientific Advisory Boards for Biogen, Merck, Novartis, Roche, Sanofi, and Teva Pharmaceuticals; has received speaker honoraria from Biogen, Merck, Novartis, Roche, Sanofi, and Teva Pharmaceuticals; CA has received honoraria for speaking, consultation fees and research grants from Biogen, Merck, Novartis, Roche, Sanofi, Bristol Myers Squibb, Alexion, and Amgen; and he is an Advisory Board member of Alexion, Amgen, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, and Sanofi. PG has received grants and personal fees from Biogen Idec, Sanofi-Genzyme, and Merck Serono; grants and personal fees from Novartis; grants from the Department of Neuroscience, University of Padua; grants from the Veneto Region of Italy; grants from the Italian Association for Multiple Sclerosis (AISM); and grants from the Italian Ministry of Public Health. CG has received fees as an invited speaker or travel expenses for attending meetings from Biogen, Genzyme, Merck Serono, Mylan, Novartis, Sanofi, Almirall, Astra Zeneca, Sandoz; MI has received grants from the Italian Multiple Sclerosis Society Foundation (FISM), the Italian National Institute of Health, and the National MS Society (NMSS); has received fees for consultation from Biogen, Bristol Myers Squibb, Genzyme, Janssen, Merck, Novartis, Roche, and Sanofi. GAM is an Advisory Board member of Biogen Idec, Sanofi-Genzyme, Merck-Serono, Novartis, F. Hoffmann-La Roche and received grant/contract support, honoraria and consultation fees from Almirall, Amgen, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, F. Hoffmann-La Roche, Mylan, Alexion, Janssen Cilag and Bristol Myers Squibb. She is the principal investigator in clinical trials for Biogen Idec, Merck Serono, Novartis, F. Hoffmann-La Roche, Sanofi-Genzyme, Merck Serono and Bristol Myers Squibb. FP has received honoraria for speaking activities from Almirall, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva Pharmaceuticals; he has served as an Advisory Board member for Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva Pharmaceuticals; received funds from Pfizer, and the Italian Multiple Sclerosis Society Foundation (FISM), for epidemiological studies.